Experimental combo aims to tackle tough lymphomas
NCT ID NCT05272384
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 39 times
Summary
This early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combination to find the safest dose and check for side effects. The goal is to see if this approach can offer a new option for patients who have run out of standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
RECRUITINGNew York, New York, 10016, United States
Contact
Contact Email: •••••@•••••
-
NYU Langone Hospital - Long Island
RECRUITINGMineola, New York, 11501, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UC Comprehensive Cancer Center at Silver Cross
RECRUITINGNew Lenox, Illinois, 60451, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Alabama at Birmingham Cancer Center
ACTIVE_NOT_RECRUITINGBirmingham, Alabama, 35233, United States
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-••••
-
University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago Medicine-Orland Park
RECRUITINGOrland Park, Illinois, 60462, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and ASTX727 (decitabine and cedazuridine)
What this could lead to
If it works, this could point toward a new treatment option for people with lymphoma that has come back or stopped responding to other therapies.
What could go wrong
This is a very early phase 1 trial with only 32 participants, so it is primarily testing safety and dosing. The combination may not work well or could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.